Veterinary vaccines are used for prevention of diseases that affect animals. Animal vaccination is a cost-effective solution to maintain animal health and sustainability, offering various benefits such as improved animal health & welfare of companion animals, improvement in livestock products, and prevention of transmission of diseases from animal to humans. Humans are largely dependent on animals, as they are the major source of milk, meat, and other dairy products. Thus, with increase in population, the demand for animal products also increases, fueling the production of vaccines for cattle, pigs, poultry, and sheep.
The growth of animal vaccines market is driven by increase in healthcare spending by governments. In addition, rise in consumption of meat, milk, and protein; and extensively growing pet ownership drive the market. However, lack of awareness toward pet health and expensive storage & production of vaccines are expected to restrain the growth of the market.
The global animal vaccines market report provides an extensive analysis of the current market trends and future estimations prevailing in the market.
The market estimations from 2014 to 2022 are based on high-end analysis of the key developments.
The market scenario is comprehensively analyzed with respect to the product type and animal type.
Recent developments and key manufacturers are listed and analyzed to understand the competitive market scenario.
In-depth geographical analysis helps to understand the regional market, which assists in strategic business planning.
KEY MARKET SEGMENTS
By Animal Type
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
The key players profiled in this report include the following:
Eli Lilly and Company
Merck & Co., Inc.
Ceva Santé Animale
The other players of the animal therapeutics and diagnostics market include (companies not profiled in the report):
PHL Associates, Inc.
Hygieia Biological Laboratories
Colorado Serum Company
Arko Laboratories, Ltd.
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2 Executive Summary
2.1. CXO Perspective
Chapter 3 Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Government Regulations
3.3.1. Center For Veterinary Biologics(Cvb)
3.4. Patents Analysis
3.4.1. Patent Analysis By Year
3.4.2. Patent Analysis By Region
3.5. Market Dynamics
220.127.116.11. Rising Demand For Animal Derived Food Products
18.104.22.168. Growing Demand For Pet Insurance
22.214.171.124. Rising Concern To Prevent Zoonotic Diseases
126.96.36.199. Growing Ownership Of Companion Animals
188.8.131.52. Rising Animal Health Expenditure
184.108.40.206. Highly Competitive Meat And Milk Prices
220.127.116.11. Lack Of Animal Health Awareness
18.104.22.168. Adverse Impact Of Veterinary Vaccines On Human And Animal Health
22.214.171.124. Advancement In Vaccine Products
126.96.36.199. Vaccine Products For Hybrid Animals
Chapter 4 Animal Vaccines Market, By Type
4.1.1. Market Size And Forecast
4.2. Attenuated Vaccines
4.2.1. Key Market Trends
4.2.2. Key Growth Factors And Opportunities
4.2.3. Market Size And Forecast
4.3. Inactivated Vaccines
4.3.1. Key Market Trends
4.3.2. Key Growth Factors And Opportunities
4.3.3. Market Size And Forecast
4.4. Subunit Vaccines
4.4.1. Key Market Trends
4.4.2. Key Growth Factors And Opportunities
4.4.3. Market Size And Forecast
4.5. Toxoid Vaccines
4.5.1. Key Market Trends
4.5.2. Key Growth Factors And Opportunities
4.5.3. Market Size And Forecast
4.6. Conjugate Vaccines
4.6.1. Key Market Trends
4.6.2. Key Growth Factors And Opportunities
4.6.3. Market Size And Forecast
4.7. Recombinant Vaccines
4.7.1. Key Market Trends
4.7.2. Key Growth Factors And Opportunities
4.7.3. Market Size And Forecast
4.8. Dna Vaccines
4.8.1. Key Market Trends
4.8.2. Key Growth Factors And Opportunities
4.8.3. Market Size And Forecast
Chapter 5 Animal Vaccines Market, By Animal Type
5.2. Companion Animals
5.2.1. Market Size And Forecast
5.2.4. Other Companion Animals
5.3.1. Market Size And Forecast
5.4.1. Market Size And Forecast
5.5.1. Market Size And Forecast
5.6.1. Market Size And Forecast
Chapter 6 Animal Vaccines Market, By Geography
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends
6.2.2. Key Growth Factors And Opportunities
6.2.3. Market Size And Forecast
6.2.4. U.S. Market Size & Forecast
6.2.5. Canada Market Size & Forecast
6.2.6. Mexico Market Size & Forecast
6.3.1. Key Market Trends
6.3.2. Key Growth Factors And Opportunities
6.3.3. Market Size And Forecast
6.3.4. Germany Market Size & Forecast
6.3.5. France Market Size & Forecast
6.3.6. Uk Market Size & Forecast
6.3.7. Italy Market Size & Forecast
6.3.8. Rest Of Europe Market Size And Forecast
6.4.1. Key Market Trends
6.4.2. Key Growth Factors And Opportunities
6.4.3. Market Size And Forecast
6.4.4. Japan Market Size & Forecast
6.4.5. China Market Size & Forecast
6.4.6. Australia Market Size & Forecast
6.4.7. India Market Size & Forecast
6.4.8. South Korea Market Size & Forecast
6.4.9. Taiwan Market Size & Forecast
6.4.10. Rest Of Asia-Pacific Market Size And Forecast
6.5.1. Key Market Trends
6.5.2. Key Growth Factors And Opportunities
6.5.3. Market Size And Forecast
6.5.4. Brazil Market Size & Forecast
6.5.5. Turkey Market Size & Forecast
6.5.6. Venezuela Market Size & Forecast
6.5.7. Saudi Arabia Market Size & Forecast
6.5.8. Rest Of Lamea Market Size And Forecast
Chapter 7 Company Profiles
7.1. Merck & Co., Inc.
7.1.1. Company Overview
7.1.2. Operating Business Segments
7.1.3. Business Performance
7.1.4. Key Strategic Moves & Developments
7.2. Zoetis Inc.
7.2.1. Company Overview
7.2.2. Operating Business Segments
7.2.3. Business Performance
7.2.4. Key Strategic Moves & Developments
7.3. Ceva Sant Animale
7.3.1. Company Overview
7.3.2. Operating Business Segments
7.3.3. Business Performance
7.4. Sanofi S.A.
7.4.1. Company Overview
7.4.2. Business Performance
7.4.3. Key Strategic Moves & Developments
7.5.1. Company Overview
7.5.2. Operating Business Segments
7.5.3. Business Performance
7.6.1. Company Overview
7.6.2. Operating Business Segments
7.6.3. Business Performance
7.7.1. Company Overview
7.7.2. Operating Business Segments
7.7.3. Business Performance
7.7.4. Key Strategic Moves & Developments
7.8.1. Company Overview
7.8.2. Operating Business Segments
7.8.3. Business Performance
7.9. Anicon Labor Gmbh
7.9.1. Company Overview
7.9.2. Business Performance
7.9.3. Key Strategic Moves & Developments
Animal vaccines are essential to ensure better animal health and welfare. Various vaccines such as attenuated vaccines, subunit vaccines, toxoid vaccines, and DNA vaccines aid to provide protection against multiple diseases, including rabies and foot & mouth disease. These vaccines offer cost-effective solutions to treat such diseases instead of excessive antibiotic administration.
Increase in adoption of companion animals in the developing countries is the major factor that drives the growth of this market. The market has witnessed moderate growth in recent years due to emerging diseases that affect livestock. The outbreak of epidemics results in severe mass wipeouts of animals, and is a growing concern for the industries dependent on products obtained through farm animals. Moreover, zoonotic diseases that affect animals pose a threat to the public health, hence avoiding transmission of such diseases via vaccination is a significant factor in disease management.
Cattle segment generated maximum revenue in 2015, accounting for over one-third share in the total revenue. This is attributed to increase in consumption of meat, milk, and dairy products, making sustainable animal health a vital aspect in disease management. However, the companion animal segment is anticipated to reach $3,209 million by 2022, registering a CAGR of 5.6%.
Attenuated vaccines segment dominated the product type segment with maximum share in 2015, in terms of revenue. Attenuated vaccines can provide stronger immunity as compared to other vaccines, which positively contributes toward the market growth.
In 2015, North America accounted for the highest revenue. Asia-Pacific is expected to show highest growth rate, registering a CAGR of 5.79%. Rise in disposable income, rise in animal healthcare expenditure, and growth in adoption of companion animals are the major factors that drive the growth of animal vaccines market in Asia-Pacific.
Key findings of the Animal Vaccines Market
DNA vaccines segment is projected to grow fastest during the analysis period.
Cattle vaccines generates highest revenue, and is expected to continue its dominance during the forecast period.
North America dominated the global animal vaccines market, and projected to grow at a CAGR of 4.5%.
China is expected to grow at the highest CAGR of 6.9 % in Asia-Pacific.
The companion animal segment exhibits fast-paced growth rate, registering a CAGR of 5.6%.
The major companies profiled in the report include Bayer AG, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Nutreco N.V., and Virbac S.A.